Numerous clinical trials evaluate eribulin mesylate across Phase 1 through Phase 4 settings, focusing primarily on HER2-negative breast cancer, triple-negative breast cancer, advanced solid tumors, and recurrent osteosarcoma. These studies assess monotherapy and combination regimens across recruitment statuses ranging from active to completed. The development landscape is supported by diverse sponsors, including pharmaceutical companies such as Eisai Inc., university medical centers, and government institutions like the National Cancer Institute.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06957431 | RECRUITING | Advanced Leiomyosarcoma; Adipocytic Sarcoma; Advanced Liposarcoma |
Washington University School of Medicine |
2025-10-22 | PHASE1 |
| NCT06255392 | RECRUITING | Fludzoparib" and Anti-angiogenic; HRD-positive/HER2-negative Advanced Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2024-06-12 | PHASE3 |
| NCT03424005 | RECRUITING | Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-03-30 | PHASE1; PHASE2 |
| NCT04579224 | ACTIVE_NOT_RECRUITING | Metastatic Bladder Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Refractory Bladder Urothelial Carcinoma; Refractory Urothelial Carcinoma; Stage IV Bladder Cancer AJCC v8 |
National Cancer Institute (NCI) |
2021-06-28 | PHASE3 |
| NCT07520760 | RECRUITING | HER 2 Negative Breast Cancer |
Sun Yat-sen University |
2026-04-01 | PHASE2 |
| NCT07173751 | RECRUITING | Breast Neoplasms |
BioNTech SE |
2025-10-30 | PHASE3 |
| NCT06875128 | RECRUITING | Metastatic Breast Cancer in the Liver |
Delcath Systems Inc. |
2026-01-29 | PHASE2 |
| NCT07406542 | NOT_YET_RECRUITING | Recurrent or Metastatic Breast Cancer |
CSPC Megalith Biopharmaceutical Co.,Ltd. |
2026-04-01 | PHASE3 |
| NCT07533123 | RECRUITING | Triple Negative Breast Cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2026-03-17 | PHASE3 |
| NCT06889688 | RECRUITING | Breast Cancer Stage IV; Triple -Negative Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-02-21 | PHASE3 |
| NCT06449222 | ACTIVE_NOT_RECRUITING | Locally Advanced Breast Cancer; Triple Negative Breast Cancer; Metastatic Triple Negative Breast Cancers |
BioNTech SE |
2024-08-26 | PHASE2 |
| NCT05530057 | RECRUITING | Advanced Breast Cancer |
Seoul National University Hospital |
2020-02-18 | PHASE2 |
| NCT04986579 | RECRUITING | Metastatic Breast Cancer; Chemotherapy-induced Alopecia |
Dana-Farber Cancer Institute |
2021-10-07 | PHASE2 |
| NCT06435429 | RECRUITING | Metastatic HER2-positive Breast Cancer |
Jazz Pharmaceuticals |
2024-08-13 | PHASE3 |
| NCT07441512 | NOT_YET_RECRUITING | TNBC - Triple-Negative Breast Cancer; TNBC |
Hu Hai |
2026-03-15 | PHASE2 |
| NCT07494448 | NOT_YET_RECRUITING | HER 2 Positive Advanced Breast Cancer; Breast Cancer |
MedSIR |
2026-07-01 | PHASE1; PHASE2 |
| NCT07461454 | RECRUITING | Locally Advanced or Metastatic Breast Cancer |
MediLink Therapeutics (Suzhou) Co., Ltd. |
2026-03-17 | PHASE3 |
| NCT07205185 | NOT_YET_RECRUITING | Soft Tissue Sarcoma (STS) |
Fudan University |
2025-10-01 | PHASE2 |
| NCT03202316 | ACTIVE_NOT_RECRUITING | Recurrent Breast Inflammatory Carcinoma; Stage IV Breast Inflammatory Carcinoma |
M.D. Anderson Cancer Center |
2017-08-11 | PHASE2 |
| NCT07007559 | RECRUITING | Breast Cancer, Metastatic |
ALX Oncology Inc. |
2025-12-10 | PHASE2 |
| NCT06263231 | RECRUITING | Sarcoma,Soft Tissue |
Intensity Therapeutics, Inc. |
2024-06-28 | PHASE3 |
| NCT07333937 | NOT_YET_RECRUITING | Brest Cancer |
Xijing Hospital |
2025-12-20 | PHASE2 |
| NCT05570253 | RECRUITING | Breast Cancer; Metastatic Triple-Negative Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2022-10-03 | PHASE2 |
| NCT07088263 | RECRUITING | Breast Neoplasms |
Sun Yat-sen University |
2025-09-15 | PHASE3 |
| NCT06942234 | RECRUITING | Inoperable Locally Advanced HER2-Negative Breast Cancer; Metastatic HER2-Negative Breast Cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2025-06-01 | PHASE1; PHASE2 |
| NCT06383767 | RECRUITING | Metastatic Breast Cancer |
Qilu Pharmaceutical Co., Ltd. |
2024-07-11 | PHASE3 |
| NCT03237780 | ACTIVE_NOT_RECRUITING | Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma; Locally Advanced Ureter Urothelial Carcinoma; Locally Advanced Urethral Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis Urothelial Carcinoma; Metastatic Ureter Urothelial Carcinoma; Metastatic Urethral Urothelial Carcinoma; Recurrent Bladder Urothelial Carcinoma; Recurrent Renal Pelvis Urothelial Carcinoma; Recurrent Ureter Urothelial Carcinoma; Recurrent Urethral Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage III Renal Pelvis Cancer AJCC v8; Stage III Ureter Cancer AJCC v8; Stage III Urethral Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis Cancer AJCC v8; Stage IV Ureter Cancer AJCC v8; Stage IV Urethral Cancer AJCC v8; Unresectable Bladder Urothelial Carcinoma; Unresectable Renal Pelvis Urothelial Carcinoma; Unresectable Ureter Urothelial Carcinoma; Unresectable Urethral Urothelial Carcinoma |
National Cancer Institute (NCI) |
2018-07-20 | PHASE2 |
| NCT06102824 | RECRUITING | HER2-negative Breast Cancer; Advanced Breast Cancer |
Guangdong Provincial People's Hospital |
2024-10-01 | PHASE2 |
| NCT05458674 | ACTIVE_NOT_RECRUITING | Breast Cancer; Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer |
Criterium, Inc. |
2024-01-30 | PHASE2 |
| NCT06731153 | NOT_YET_RECRUITING | Triple Negative Breast Cancer (TNBC); Metastatic Breast Cancer |
Fudan University |
2024-12 | PHASE2 |
| NCT06590558 | WITHDRAWN | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Locally Advanced HER2-Negative Breast Carcinoma; Locally Advanced Hormone Receptor-Positive Breast Carcinoma; Locally Advanced Triple-Negative Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Hormone Receptor-Positive Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2025-08-04 | PHASE1 |
| NCT06957886 | RECRUITING | HER2-low Breast Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2025-05-15 | PHASE3 |
| NCT06328738 | ACTIVE_NOT_RECRUITING | HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors; HER2 Amplification; Colorectal Cancer |
Enliven Therapeutics |
2024-05-30 | PHASE1 |
| NCT06006273 | RECRUITING | Refractory Solid Tumors |
M.D. Anderson Cancer Center |
2023-08-16 | PHASE1 |
| NCT06081959 | RECRUITING | Metastatic Breast Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2023-10-31 | PHASE3 |
| NCT07255612 | NOT_YET_RECRUITING | Breast Cancer |
Sun Yat-sen University |
2026-11-04 | PHASE2 |
| NCT06202261 | RECRUITING | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2023-04-13 | PHASE1; PHASE2 |
| NCT04639986 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Gilead Sciences |
2020-11-23 | PHASE3 |
| NCT06519370 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
2024-08-09 | PHASE3 |
| NCT06343948 | ACTIVE_NOT_RECRUITING | HR+HER2- Breast Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2024-04-24 | PHASE3 |
| NCT06857305 | UNKNOWN | Breast Cancer Metastatic |
Ma Fei，MD |
2023-07-13 | PHASE3 |
| NCT06279364 | RECRUITING | Triple Negative Breast Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2024-02-28 | PHASE3 |
| NCT05063786 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Spanish Breast Cancer Research Group |
2021-09-14 | PHASE3 |
| NCT05238831 | WITHDRAWN | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2023-01-30 | EARLY_PHASE1 |
| NCT06079983 | RECRUITING | Breast Cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2023-12-01 | PHASE3 |
| NCT06387628 | RECRUITING | TNBC - Triple-Negative Breast Cancer |
Fudan University |
2024-07-10 | PHASE2 |
| NCT05810870 | ACTIVE_NOT_RECRUITING | Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer |
MedSIR |
2023-05-24 | PHASE2 |
| NCT05814354 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2023-06-30 | PHASE3 |
| NCT06268652 | RECRUITING | Breast Cancer; Refractory Breast Carcinoma |
Sun Yat-sen University |
2024-01-15 | PHASE3 |
| NCT06539559 | UNKNOWN | Breast Neoplasms; Neoplasm Metastasis; Drug Therapy; Bevacizumab |
Wang Jiayu |
2024-08-01 | PHASE2 |
| NCT06382142 | ACTIVE_NOT_RECRUITING | Triple-Negative Breast Cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
2024-06-21 | PHASE3 |
| NCT06308939 | UNKNOWN | Metastatic Breast Cancer |
Zhejiang Cancer Hospital |
2024-03-08 | PHASE2 |
| NCT06202313 | NOT_YET_RECRUITING | Triple Negative Breast Cancer |
Shengjing Hospital |
2024-02-10 | PHASE2 |
| NCT06143553 | UNKNOWN | Metastatic Breast Cancer (MBC) |
Shanghai Yizhong Pharmaceutical Co., Ltd. |
2023-09-25 | PHASE3 |
| NCT05824975 | RECRUITING | Advanced Solid Tumor; Metastatic Solid Tumor; Soft Tissue Sarcoma (STS); Platinum-resistant Ovarian Cancer (PROC); Hepatocellular Carcinoma (HCC); Colorectal Cancer (CRC); HER2 Negative Breast Cancer; Cutaneous Melanoma; Renal Cell Carcinoma (RCC) |
GI Innovation, Inc. |
2023-05-30 | PHASE1; PHASE2 |
| NCT06678230 | UNKNOWN | Breast Cancer |
The First Hospital of Jilin University |
2024-11 | PHASE2 |
| NCT05374512 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2022-05-16 | PHASE3 |
| NCT00365157 | ACTIVE_NOT_RECRUITING | Advanced Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage IV Bladder Urothelial Carcinoma AJCC v7; Unresectable Urothelial Carcinoma |
National Cancer Institute (NCI) |
2006-10-23 | PHASE1; PHASE2 |
| NCT05335473 | UNKNOWN | HR Positive HER2 Negative Advanced Breast Cancer |
Henan Cancer Hospital |
2022-05-13 | PHASE1; PHASE2 |
| NCT05619913 | COMPLETED | Ovarian Carcinosarcoma; Uterine Carcinosarcoma |
Australia New Zealand Gynaecological Oncology Group |
2023-05-22 | PHASE2 |
| NCT02344472 | UNKNOWN | Metastatic Breast Cancer |
Prof. Wolfgang Janni |
2015-09 | PHASE3 |
| NCT06355024 | COMPLETED | Triple-negative Breast Cancer |
Fudan University |
2024-05-11 | PHASE2 |
| NCT05760378 | RECRUITING | Triple-Negative Breast Cancer |
Fudan University |
2023-03-17 | PHASE3 |
| NCT03264547 | COMPLETED | Breast Cancer |
Japan Breast Cancer Research Group |
2017-08-28 | PHASE3 |
| NCT06355037 | UNKNOWN | Triple-negative Breast Cancer |
Fudan University |
2024-05-20 | PHASE2 |
| NCT06533722 | COMPLETED | HER2-negative Metastatic Breast Cancer |
Sun Yat-sen University |
2024-08-04 | PHASE2 |
| NCT03840772 | COMPLETED | Solitary Fibrous Tumor |
Italian Sarcoma Group |
2019-07-17 | PHASE2 |
| NCT02419495 | TERMINATED | Advanced Malignant Solid Neoplasm; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Fallopian Tube Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Ovarian Carcinoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Primary Peritoneal Carcinoma; Stage III Lung Cancer AJCC v8; Stage III Renal Cell Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Melanoma; Unresectable Renal Cell Carcinoma |
M.D. Anderson Cancer Center |
2015-06-26 | PHASE1 |
| NCT05041101 | TERMINATED | Breast Inflammatory Carcinoma; Recurrent Breast Inflammatory Carcinoma; Stage IV Breast Inflammatory Carcinoma |
M.D. Anderson Cancer Center |
2021-12-21 | PHASE1; PHASE2 |
| NCT05104866 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2021-10-18 | PHASE3 |
| NCT03899805 | COMPLETED | Sarcoma; Liposarcoma; Leiomyosarcoma; Undifferentiated Pleomorphic Sarcoma |
Dana-Farber Cancer Institute |
2019-06-04 | PHASE2 |
| NCT04345913 | ACTIVE_NOT_RECRUITING | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Unresectable Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2021-03-01 | PHASE1; PHASE2 |
| NCT05945368 | UNKNOWN | HER2-positive Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-02-25 | PHASE2 |
| NCT02035813 | COMPLETED | HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer; HER2-negative Circulating Tumor Cells; Postmenopausal Female Patients |
Prof. Wolfgang Janni |
2014-01 | PHASE2 |
| NCT05263882 | UNKNOWN | HER2-negative Breast Cancer |
Fifth Affiliated Hospital, Sun Yat-Sen University |
2022-03 | PHASE2 |
| NCT04464174 | COMPLETED | Triple Negative Breast Cancer |
MedSIR |
2020-10-08 | PHASE2 |
| NCT03901339 | COMPLETED | Metastatic Breast Cancer |
Gilead Sciences |
2019-05-08 | PHASE3 |
| NCT04681911 | UNKNOWN | Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2020-09-09 | PHASE2 |
| NCT05033769 | UNKNOWN | Breast Cancer Female; Neoplasm, Breast; Breast Cancer Metastatic |
Institut fuer Frauengesundheit |
2021-03-11 | PHASE4 |
| NCT05833919 | UNKNOWN | Metastatic Breast Cancer |
Consorzio Oncotech |
2018-07-30 | PHASE2 |
| NCT04502680 | UNKNOWN | Triple Negative Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2021-06 | PHASE2 |
| NCT03361436 | ACTIVE_NOT_RECRUITING | Liposarcoma; Malignant Abdominal Neoplasm; Malignant Retroperitoneal Neoplasm; Malignant Scrotal Neoplasm; Malignant Solid Neoplasm; Malignant Spermatic Cord Neoplasm |
OHSU Knight Cancer Institute |
2018-03-19 | PHASE1 |
| NCT04745975 | UNKNOWN | Triple Negative Breast Cancer |
Fudan University |
2021-02-01 | PHASE2 |
| NCT05402722 | UNKNOWN | TNBC - Triple-Negative Breast Cancer |
Beijing 302 Hospital |
2022-01-01 | PHASE2 |
| NCT05546255 | UNKNOWN | Triple Negative Breast Cancer |
Chinese Academy of Medical Sciences |
2020-06-01 | PHASE2 |
| NCT02299999 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
UNICANCER |
2014-04-07 | PHASE2 |
| NCT04303741 | UNKNOWN | Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2020-03-25 | PHASE2 |
| NCT03579472 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2018-05-30 | PHASE1 |
| NCT04517292 | UNKNOWN | Breast Cancer |
Fudan University |
2020-10-08 | PHASE2 |
| NCT04913571 | UNKNOWN | Triple Negative Breast Cancer |
Fudan University |
2021-05-27 | PHASE2 |
| NCT04624711 | UNKNOWN | HER2-negative Breast Cancer |
The First Affiliated Hospital with Nanjing Medical University |
2021-03-01 | PHASE2 |
| NCT03810976 | COMPLETED | Sarcoma |
Yonsei University |
2018-03-27 | PHASE2 |
| NCT05206656 | COMPLETED | Metastatic Breast Cancer |
Hunan Cancer Hospital |
2020-10-09 | PHASE2 |
| NCT04061863 | UNKNOWN | Metastatic Breast Cancer |
Seoul National University Hospital |
2019-08-01 | PHASE1; PHASE2 |
| NCT03331250 | COMPLETED | Angiosarcoma; Epithelioid Hemangioendothelioma |
Massachusetts General Hospital |
2018-01-18 | PHASE2 |
| NCT04826016 | WITHDRAWN | Advanced Breast Cancer |
MedSIR |
2022-03-16 | PHASE1; PHASE2 |
| NCT04013217 | TERMINATED | Solid Tumor |
Health Hope Pharma |
2019-07-29 | PHASE1 |
| NCT05134194 | TERMINATED | Triple Negative Breast Cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
2022-01-17 | PHASE3 |
| NCT03734029 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Daiichi Sankyo |
2018-12-27 | PHASE3 |
| NCT02824575 | TERMINATED | Breast Cancer; Breast Adenocarcinoma; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Recurrent Breast Carcinoma; Stage IV Breast Cancer |
Montefiore Medical Center |
2016-07 | PHASE1 |
| NCT03786094 | TERMINATED | Metastatic Breast Cancer; Locally Recurrent Breast Cancer |
Spexis AG |
2019-05-30 | PHASE3 |
| NCT03526679 | COMPLETED | Leiomyosarcoma; Liposarcoma; Soft Tissue Sarcoma Adult; Advanced Cancer |
National Taiwan University Hospital |
2018-07-12 | PHASE1; PHASE2 |
| NCT03245450 | COMPLETED | Refractory or Recurrent Solid Tumors; Rhabdomyosarcoma; Non-Rhabdomyosarcoma Soft Tissue Sarcoma; Ewing Sarcoma |
Eisai Inc. |
2018-03-05 | PHASE1; PHASE2 |
| NCT02623972 | ACTIVE_NOT_RECRUITING | Inflammatory Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
Dana-Farber Cancer Institute |
2016-02-26 | PHASE2 |
| NCT03795012 | TERMINATED | Breast Cancer |
MedSIR |
2019-04-30 | PHASE2 |
| NCT01676818 | COMPLETED | Recurrent Cervical Cancer; Stage IIIA Cervical Cancer; Stage IIIB Cervical Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer |
University of Southern California |
2012-08-09 | PHASE2 |
| NCT02037529 | SUSPENDED | Breast Adenocarcinoma; HER2/Neu Negative; Invasive Breast Carcinoma; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 |
Academic and Community Cancer Research United |
2014-01-17 | PHASE3 |
| NCT03441360 | COMPLETED | Relapsed/Refractory Rhabdomyosarcoma; Non-rhabdomyosarcoma Soft Tissue Sarcoma; Ewing Sarcoma |
Eisai Inc. |
2018-04-17 | PHASE2 |
| NCT02404506 | TERMINATED | Breast Cancer; Adenocarcinoma |
Swiss Cancer Institute |
2015-08-17 | PHASE2 |
| NCT02640508 | COMPLETED | Cancer; Solid Tumor |
Virginia G. Kaklamani |
2016-05 | PHASE2 |
| NCT01593020 | COMPLETED | Breast Cancer |
M.D. Anderson Cancer Center |
2012-08-03 | PHASE2 |
| NCT02915744 | COMPLETED | Metastasis; Breast Cancer |
Nektar Therapeutics |
2016-11 | PHASE3 |
| NCT01372579 | UNKNOWN | Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer |
Northwestern University |
2011-08 | PHASE2 |
| NCT03412955 | UNKNOWN | Breast Cancer |
Tan Tock Seng Hospital |
2017-03-08 | PHASE2 |
| NCT03637868 | WITHDRAWN | Metastatic Breast Cancer |
Institut Paoli-Calmettes |
2019-02-26 | PHASE2 |
| NCT02574455 | COMPLETED | Breast Cancer |
Gilead Sciences |
2017-11-07 | PHASE3 |
| NCT03430518 | COMPLETED | HER2-Negative Metastatic Breast Cancer; Recurrent Ovarian Cancer |
Amy Tiersten |
2018-05-17 | PHASE1 |
| NCT01554371 | COMPLETED | Malignant Solid Tumour; Breast Cancer Nos Metastatic Recurrent; Neuropathy |
University of California, San Francisco |
2012-03-27 | PHASE1; PHASE2 |
| NCT03502681 | TERMINATED | Metastatic Urothelial Cell Cancer |
Monika Joshi, MD |
2018-06-12 | PHASE1 |
| NCT02753595 | TERMINATED | Metastatic Breast Cancer |
Eisai Inc. |
2016-07-13 | PHASE1; PHASE2 |
| NCT02513472 | COMPLETED | Breast Neoplasm |
Eisai Inc. |
2015-08-28 | PHASE1; PHASE2 |
| NCT03583944 | COMPLETED | Breast Neoplasms |
Eisai Inc. |
2018-03-28 | PHASE4 |
| NCT01908101 | COMPLETED | Recurrent Breast Carcinoma; Stage IV Breast Cancer |
University of Washington |
2014-01-08 | PHASE2 |
| NCT02555657 | COMPLETED | Metastatic Triple Negative Breast Cancer |
Merck Sharp & Dohme LLC |
2015-10-13 | PHASE3 |
| NCT02596503 | COMPLETED | Relapsed Solid Tumors; Refractory Solid Tumors |
University of Colorado, Denver |
2015-10-21 | PHASE1 |
| NCT03032614 | WITHDRAWN | Breast Cancer Stage IV; Ovarian Cancer; BRCA1 Mutation; BRCA2 Mutation |
The University of Texas Health Science Center at San Antonio |
2017-09-30 | PHASE2 |
| NCT02120469 | COMPLETED | Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor-negative; Stage IV Breast Cancer; Triple-negative Breast Carcinoma |
City of Hope Medical Center |
2014-10-01 | PHASE1 |
| NCT02178241 | COMPLETED | Metastatic Ureter Carcinoma; Metastatic Urethral Carcinoma; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Ureter Cancer AJCC v7; Stage III Urethral Cancer AJCC v7; Stage IV Bladder Urothelial Carcinoma AJCC v7; Stage IV Ureter Cancer AJCC v7; Stage IV Urethral Cancer AJCC v7; Ureter Urothelial Carcinoma; Urethral Urothelial Carcinoma |
National Cancer Institute (NCI) |
2014-12-11 | PHASE2 |
| NCT02864030 | COMPLETED | Metastatic Breast Cancer; Toxicity; Neurotoxicity; Drug Toxicity; Adverse Drug Event |
Oncologia Medica dell'Ospedale Fatebenefratelli |
2014-05 | PHASE4 |
| NCT02514681 | COMPLETED | HER2-positive Locally Advanced or Metastatic Breast Cancer |
Japan Breast Cancer Research Group |
2015-08-01 | PHASE3 |
| NCT03222856 | COMPLETED | Breast Cancer |
MedSIR |
2017-12-14 | PHASE2 |
| NCT03051659 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2017-03-22 | PHASE2 |
| NCT02723877 | COMPLETED | Metastatic Breast Cancer |
PIQUR Therapeutics AG |
2016-03-28 | PHASE1; PHASE2 |
| NCT01837095 | COMPLETED | Metastatic Breast Cancer |
Polyphor Ltd. |
2013-06 | PHASE1 |
| NCT02681523 | TERMINATED | Breast Cancer |
Imperial College London |
2015-10-28 | PHASE2 |
| NCT02581839 | COMPLETED | Metastatic Breast Cancer; Brain Metastases |
Case Comprehensive Cancer Center |
2015-11-17 | PHASE2 |
| NCT02082626 | TERMINATED | Pediatric Cancer; Solid Tumors; Lymphoma |
University of Oklahoma |
2014-02-01 | PHASE1 |
| NCT02014337 | COMPLETED | Breast Cancer; Ovarian Epithelial Cancer Recurrent; Sarcoma; Non-small Cell Lung Cancer; Carcinoma, Transitional Cell; Prostate Cancer; Prostatic Neoplasms |
Corcept Therapeutics |
2014-01 | PHASE1 |
| NCT02225470 | COMPLETED | HER2-Negative Breast Cancer; Triple Negative Breast Cancer; Breast Cancer; Cancer of Breast; Breast Tumors |
Eisai Co., Ltd. |
2013-09-26 | PHASE3 |
| NCT01613768 | COMPLETED | Recurrent Salivary Gland Cancer; Stage IVA Salivary Gland Cancer; Stage IVB Salivary Gland Cancer; Stage IVC Salivary Gland Cancer |
University of Washington |
2012-05-08 | PHASE2 |
| NCT02338037 | COMPLETED | Metastatic Malignant Neoplasm in the Adult Brain; Primary Brain Tumor |
City of Hope Medical Center |
2015-05-19 | EARLY_PHASE1 |
| NCT02215876 | WITHDRAWN | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-09 | PHASE2 |
| NCT01596751 | COMPLETED | Metastatic Breast Cancer |
Hope Rugo, MD |
2012-07-12 | PHASE1; PHASE2 |
| NCT02263495 | COMPLETED | Metastatic Breast Cancer |
Asan Medical Center |
2014-12-19 | PHASE2 |
| NCT01401959 | COMPLETED | Metastatic Breast Cancer |
SCRI Development Innovations, LLC |
2011-09-23 | PHASE2 |
| NCT02481050 | COMPLETED | Breast Cancer |
Eisai Inc. |
2015-06-16 | PHASE2 |
| NCT02175446 | UNKNOWN | Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
Consorzio Oncotech |
2014-09 | PHASE2 |
| NCT01912963 | TERMINATED | HER2-positive Breast Cancer; Metastatic Breast Cancer |
Dana-Farber Cancer Institute |
2013-09 | PHASE2 |
| NCT01827787 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2013-05 | PHASE2 |
| NCT02171260 | COMPLETED | Pediatrics; Solid Tumors |
Eisai Inc. |
2014-07-31 | PHASE1 |
| NCT02841722 | COMPLETED | Breast Cancer |
Centre Georges Francois Leclerc |
2015-12-03 | |
| NCT02061085 | COMPLETED | Breast Neoplasm; Metastasis |
MedSIR |
2013-07 | PHASE2 |
| NCT02616848 | UNKNOWN | Triple Negative Breast Cancer |
Istituti Ospitalieri di Cremona |
2015-11 | PHASE1 |
| NCT02000596 | TERMINATED | Metastatic Breast Cancer |
University of Maryland, Baltimore |
2014-01 | PHASE2 |
| NCT01945710 | COMPLETED | Solid Tumors |
Eisai Limited |
2012-12-11 | PHASE1 |
| NCT01585870 | COMPLETED | Neoplasms |
Bayer |
2012-07 | PHASE1 |
| NCT01961544 | COMPLETED | Breast Neoplasms; Breast Cancer |
Eisai Korea Inc. |
2013-06 | PHASE4 |
| NCT02097238 | COMPLETED | Recurrent Osteosarcoma |
National Cancer Institute (NCI) |
2014-08 | PHASE2 |
| NCT01498588 | TERMINATED | Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast |
Emory University |
2011-11 | PHASE2 |
| NCT01669252 | COMPLETED | Breast Cancer |
SOLTI Breast Cancer Research Group |
2012-08 | PHASE2 |
| NCT01126749 | TERMINATED | Bladder Cancer |
Eisai Inc. |
2010-04-16 | PHASE1; PHASE2 |
| NCT02396433 | WITHDRAWN | Cancer of the Breast |
The University of Texas Health Science Center at San Antonio |
2015-04 | PHASE1; PHASE2 |
| NCT01744340 | COMPLETED | Head and Neck Cancer; Colon Cancer |
howard safran |
2012-05 | PHASE1; PHASE2 |
| NCT01534455 | TERMINATED | Metastatic Breast Cancer |
GBG Forschungs GmbH |
2012-02 | PHASE2 |
| NCT01795586 | COMPLETED | Breast Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2013-02-06 | PHASE1 |
| NCT01327885 | COMPLETED | Soft Tissue Sarcoma |
Eisai Inc. |
2011-03-10 | PHASE3 |
| NCT01458249 | COMPLETED | Soft Tissue Sarcoma |
Eisai Co., Ltd. |
2011-11 | PHASE2 |
| NCT01328249 | COMPLETED | HER2-normal |
Eisai Inc. |
2011-03-03 | PHASE2 |
| NCT01527487 | COMPLETED | HER2 Negative Breast Cancer |
SCRI Development Innovations, LLC |
2012-06 | PHASE2 |
| NCT01941407 | COMPLETED | Metastatic Breast Cancer |
ARCAGY/ GINECO GROUP |
2013-11 | PHASE2 |
| NCT01323530 | COMPLETED | Metastatic Breast Cancer |
Eisai Limited |
2010-01-26 | PHASE1; PHASE2 |
| NCT01388647 | TERMINATED | HER-2 Positive Breast Cancer |
Vector Oncology |
2011-08 | PHASE1; PHASE2 |
| NCT01454934 | COMPLETED | Non-Small Cell Lung Cancer (NSCLC) |
Eisai Inc. |
2011-12-09 | PHASE3 |
| NCT00415324 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2006-12 | PHASE1 |
| NCT01705691 | COMPLETED | Breast Cancer; HER2-negative Breast Cancer |
NSABP Foundation Inc |
2012-09 | PHASE2 |
| NCT01427933 | COMPLETED | Breast Cancer |
Eli Lilly and Company |
2011-11 | PHASE2 |
| NCT01432886 | COMPLETED | Breast Cancer |
Eisai Co., Ltd. |
2011-10 | PHASE1 |
| NCT00879086 | COMPLETED | Breast Cancer |
Eisai Inc. |
2009-03-31 | PHASE2 |
| NCT01269346 | COMPLETED | Breast Cancer |
Eisai Inc. |
2010-12 | PHASE2 |
| NCT01126736 | COMPLETED | Non Small Cell Lung Cancer |
Eisai Inc. |
2010-06-10 | PHASE1; PHASE2 |
| NCT01439282 | COMPLETED | Estrogen Receptor Positive Tumor; Breast Cancer |
Eisai Inc. |
2011-08 | PHASE2 |
| NCT00410553 | COMPLETED | Adult Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Uterine Corpus Carcinoma; Stage III Ovarian Cancer AJCC v6 and v7; Stage III Uterine Corpus Cancer AJCC v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Uterine Corpus Cancer AJCC v7 |
National Cancer Institute (NCI) |
2006-11-14 | PHASE1 |
| NCT00337103 | COMPLETED | Metastatic Breast Cancer |
Eisai Inc. |
2006-09-20 | PHASE3 |
| NCT01268150 | COMPLETED | Locally Recurrent; Metastatic Breast Cancer ( HER2 Negative) |
Eisai Inc. |
2011-02 | PHASE2 |
| NCT00334893 | COMPLETED | Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Recurrent Ovarian Epithelial Cancer |
National Cancer Institute (NCI) |
2006-04 | PHASE2 |
| NCT01142661 | COMPLETED | Breast Cancer |
Eisai Inc. |
2010-08 | |
| NCT00383760 | COMPLETED | Adenocarcinoma of the Pancreas; Pancreatic Cancer; Recurrent Pancreatic Cancer; Stage II Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer |
National Cancer Institute (NCI) |
2006-08 | PHASE2 |
| NCT00908908 | COMPLETED | Advanced Solid Tumors |
Eisai Inc. |
2009-03 | PHASE1 |
| NCT01104155 | COMPLETED | Non-small Cell Lung Cancer |
Eisai Inc. |
2010-02-22 | PHASE2 |
| NCT03002493 | COMPLETED | Tumor |
Eisai Limited |
2009-12 | PHASE1 |
| NCT00400829 | COMPLETED | Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer |
National Cancer Institute (NCI) |
2006-11 | PHASE2 |
| NCT00965523 | COMPLETED | Breast Cancer |
Eisai Co., Ltd. |
2008-01 | PHASE2 |
| NCT01106248 | COMPLETED | Advanced Solid Tumor |
Eisai Limited |
2009-03 | PHASE1 |
| NCT00706095 | COMPLETED | Cancer |
Eisai Inc. |
2008-02 | PHASE1 |
| NCT01000376 | COMPLETED | Cancer |
Eisai Limited |
2009-02 | PHASE1 |
| NCT00337077 | COMPLETED | Adenocarcinoma of the Prostate; Hormone-refractory Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer |
National Cancer Institute (NCI) |
2006-11 | PHASE2 |
| NCT00337129 | COMPLETED | Head and Neck Cancer |
National Cancer Institute (NCI) |
2006-05 | PHASE2 |
| NCT00047034 | COMPLETED | Unspecified Adult Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2002-08 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-06-03)
Check the
Eribulin Mesylate (E7389)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Eribulin Mesylate (E7389) Solubility in DMSO
- Eribulin Mesylate (E7389) Stock Solution
- Eribulin Mesylate (E7389) Storage
- Eribulin Mesylate (E7389) Stability
- Eribulin Mesylate (E7389) Molecular Weight
- Eribulin Mesylate (E7389) CAS Number
- Eribulin Mesylate (E7389) Chemical Structure (2D and 3D)
- Eribulin Mesylate (E7389) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.